1-(6-Chloro-2'-fluoro-6'-methoxy-[1,1'-biphenyl]-3-yl)-3-(1-(2-chloroacetyl)piperidin-4-yl)urea

ID: ALA5283825

Chembl Id: CHEMBL5283825

Max Phase: Preclinical

Molecular Formula: C21H22Cl2FN3O3

Molecular Weight: 454.33

Associated Items:

Names and Identifiers

Canonical SMILES:  COc1cccc(F)c1-c1cc(NC(=O)NC2CCN(C(=O)CCl)CC2)ccc1Cl

Standard InChI:  InChI=1S/C21H22Cl2FN3O3/c1-30-18-4-2-3-17(24)20(18)15-11-14(5-6-16(15)23)26-21(29)25-13-7-9-27(10-8-13)19(28)12-22/h2-6,11,13H,7-10,12H2,1H3,(H2,25,26,29)

Standard InChI Key:  YROMFVOACNMBIH-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA5283825

    ---

Associated Targets(Human)

NCI-H358 (882 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NCI-H23 (49055 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
A549 (127892 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NCI-H2228 (1030 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 454.33Molecular Weight (Monoisotopic): 453.1022AlogP: 4.51#Rotatable Bonds: 5
Polar Surface Area: 70.67Molecular Species: NEUTRALHBA: 3HBD: 2
#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 13.38CX Basic pKa: CX LogP: 3.13CX LogD: 3.13
Aromatic Rings: 2Heavy Atoms: 30QED Weighted: 0.65Np Likeness Score: -1.64

References

1. Cheng R, Lv X, Bu H, Xu Q, Wu J, Xie K, Tang J, Wang L, Zhuang J, Zhang Y, Zhang Y, Yan C, Lai Y..  (2022)  Design, synthesis, and evaluation of 4(1H)-quinolinone and urea derivatives as KRASG12C inhibitors with potent antitumor activity against KRAS-mutant non-small cell lung cancer.,  244  [PMID:36228411] [10.1016/j.ejmech.2022.114808]

Source